Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System.
Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Sex differences in autoimmune diseases.
Cerebellar cortical demyelination in the murine cuprizone model.
Experimental models of spontaneous autoimmune disease in the central nervous system.
The neuroendocrine axis in patients with multiple sclerosis.
Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases.
A New Colour Reaction on Copper and Certain Carbonyl Compounds
IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients
Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects.
Sex differences in autoimmune disease.
MHC transmission: insights into gender bias in MS susceptibility.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Cerebrospinal fluid data compilation and knowledge-based interpretation of bacterial, viral, parasitic, oncological, chronic inflammatory and demyelinating diseases. Diagnostic patterns not to be missed in neurology and psychiatry.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Immunopathogenesis of neuromyelitis optica.
Firategrast: natalizumab in a pill?
Spectrophotometric Determination of Serum Copper with Biscyclohexanoneoxalyldihydrazone
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking.
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent.
Best practice in the use of natalizumab in multiple sclerosis.
Pages
« first
‹ previous
…
16
17
18
19
20
21
22
23
24
…
next ›
last »